

सं. / No. 50014/03/2020-CDN
भारत सरकार / Government of India
रसायन एवं उर्वरक मंत्रालय / Ministry of Chemicals and Fertilizers
औषध विभाग / Department of Pharmaceuticals

जी-25, शास्त्री भवन, नई दिल्ली
G-25, Shastri Bhawan, New Delhi
Dated: 22nd May, 2024

OFFICE MEMORANDUM

Subject: Monthly Summary Report in respect of Department of Pharmaceuticals for the month of April, 2024-reg.

The undersigned is directed to circulate herewith a copy of the Monthly Summary pertaining to the Department of Pharmaceuticals for the month of April, 2024 for information.

Meera Mamgaain
22/05/2024

(Meera Mamgaain)

Under Secretary to the Govt. of India

Tel. 011-23716517

To,

1. All members of Council of Ministers.
2. Vice Chairman, NITI Aayog, Yojana Bhawan, New Delhi.
3. The Principal Information Officer, M/o Information and Broadcasting, Shastri Bhawan, New Delhi.

Copy to:

1. Secretaries to the Govt. of India, All Ministries/Department.
2. The Chairman, UPSC, Shahajahan Road, New Delhi-110069.
3. Secretary to President of India (Rashtrapati Ke Sachiv), Rashtrapati Bhawan, New Delhi-110004.
4. Secretary to Vice- President of India (Uprashtrapati Ke Sachiv), New Delhi-110004.
5. PS to Prime Minister of India, South Block, New Delhi-110004.
6. Director, Cabinet Secretariat, Rashtrapati Bhawan, New Delhi-110004.
7. Sr. PPS to Secretary (Pharma).
8. Director (NIC), Department of Pharmaceuticals, Shastri Bhawan, New Delhi.

**Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals**

1. Important policy decisions taken and major achievements during the month of April 2024:

A. National Institutes of Pharmaceutical Education & Research (NIPERs):

National Policy on Research & Development and Innovation in the Pharma-Meditech Sector:

The Cabinet has approved the National Policy on Research & Development and Innovation in the Pharma-Meditech Sector in India in its meeting held on 25.07.2023. The Policy was notified on 18.08.2023. R&D Policy envisages setting up of Indian Council for Pharmaceuticals and Meditech Research and Development (ICPMR) which has been constituted vide DOP O.M. dated 05.03.2024 with the approval of the Hon'ble Minister of Chemicals & Fertilizers. The Department has developed a portal for monitoring the implementation of the R&D Policy that is operational since April 2, 2024.

Research Papers, Patents and MoUs:

- 62 research papers have been published in the month of April, 2024.
- 01 Patent filed during the month of April 2024.
- 03 MoUs signed in the month of April 2024.

Workshops/Seminars/Training and other events:

- DoP officials visited NIPER Hyderabad on April 18, 2024 to review the progress in construction of its permanent campus.
- NIPER Hyderabad celebrated World Earth Day on 22nd April, 2024.
- NIPER Kolkata invited a talk on application of Ansys software for advanced healthcare simulation on April 15, 2024.
- NIPER Kolkata conducted a demo session on Knimbus Online Library Solution (Knimbus mLibrary Demo) on April 15, 2024.
- NIPER Kolkata organized a training session on Reaxys access to science direct journals for NIPER accelerate your research with Reaxys on April 18, 2024.
- NIPER Mohali conducted a one-week hands-on training on HPLC during April 1-5, 2024.
- NIPER Mohali conducted a special leadership talk for female students of the institute on April 12, 2024.
- NIPER Mohali conducted a seminar on 'HDAC Inhibitor: A case study in drug discovery' on April 16, 2024.
- NIPER Mohali conducted a seminar on 'PROTAC for targeted degradation of apoptosis signal regulating kinase 1 (ASK1)- our approach for treating NAFLD / NASH' on April 19, 2024.
- NIPER Mohali conducted a seminar on "In the quest for new anti-inflammatory and anti-tuberculosis chemotypes: sustainable medicinal chemistry approaches" on April 24, 2024.
- NIPER Guwahati organized workshop on hands-on computer-aided drug design on April 2-3, 2024.
- NIPER Guwahati organised hands-on training session on "Next generation sequencing principle, chemistry and analysis" on April 10, 2024.
- NIPER-Hajipur organised "Scientific Talk on Artificial Intelligence and its application in the field of Clinical Oncology" on April 16, 2024.

- NIPER-Raebareli celebrated 'World Creativity and Innovation Day' by organizing a two-day workshop - 'Monolith X', on April 27-28, 2024.
- NIPER-Raebareli celebrated Sports Week "KSHITIZ-2024" during the 1st week of April, 2024.
- NIPER-Raebareli has signed Memorandums of Understanding (MOUs) with Leuitis Pharmaceuticals LLP, Hyderabad, and the Biophore Group of Companies, Hyderabad.

B. National Pharmaceutical Pricing authority (NPPA):

- During the month of April, 2024, draft ceiling price worksheet for 07 scheduled formulations under NLEM 2022 and draft retail price worksheet of 38 formulations were uploaded on website of NPPA.
- As part of enforcement activities, NPPA received an amount of Rs.1,75,25,346/- towards overcharging amount.
- On the basis of monitoring and enforcement activities, Enforcement Division of NPPA has issued one hundred and twenty-two preliminary notices (PN) for price violations.
- NPPA through Price Monitoring and Resource Units (PMRUs) in the States/UTs conducted 4 market surveys in April 2024 to track and assess the availability of COVID management drugs.

C. Schemes:

(i) Status of Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP):

Number of PMBJP Kendras functional		Sales under PMBJP at MRP Value (Rs. in Crore) and saving to common man during the month of April, 2024		Product basket (As on 30.04.2024)		Sale of Suvidha Sanitary Napkins @ Rs. 1/- per pad during the month April, 2024	Incentive provided in the month April, 2024
April 2024	Cumulative (As on 30.04.2024)	Sale Rs. (in Cr.)	Saving Rs. (in Cr.) (Approx.)	Medicines	Surgical		
458	11719	138.46	692.30	2047	300	Rs.1.74 Crore	Rs.8.84 Crore

(ii) Status of PLI Schemes

S. No.	Name of Scheme		Total No. of Applications Received	Total no. of applications approved as on date
1.	Production Linked Incentive Scheme for Bulk Drug (Last EC Meeting held on 26.03.2024 on PLI Bulk Drugs)	Round 1	215	38
		Round 2	24	07
		Round 3	09	02
		Round 4	01	01

		Total	249	48
2.	Production Linked Incentive Scheme for Medical Device (Last EC Meeting held on 26.03.2024 on Medical Devices)	Round 1	28	11
		Round 2	14	08
		Round 3	18	05
		Round 4	04	02
		Total	64	26
3.	Production Linked Incentive scheme for Pharmaceuticals		278	55

(iii) Actual progress made under the PLI Schemes as on April, 2024 are as follows:

Details	PLI Bulk Drugs	PLI Pharmaceuticals	PLI Medical Devices
Actual Investment (Rs. in Cr.)	3715	28,328	958.72
Actual Production (Rs. in Cr.)	968	1,43,553	5889.29
Actual Employment (No. of persons)	2,994	59,768	5466
Project Commissioned	30	261 manufacturing locations	17

Note: Progress reflected is cumulative progress till 30.04.2024

D. International Cooperation:

(i) DoP participated in the 18th Session of India - Belgium Luxembourg Economic Union (BLEU) Joint Economic Commission (JEC) held on 9th April 2024 in New Delhi wherein collaboration in pharmaceuticals, vaccines and medical devices was discussed.

(ii) Economic Advisor, DoP participated in the co-branded event under the theme of “Key success factors for local and regional production of Vaccines, Therapeutics and Diagnostics (VTD)” of G-20 Brazil Presidency 2024 on 10th April 2024 hosted by GAVI and participated as a panellist in the session titled “The Rationale and Benefits of Local and Regional Production.”

(iii) DoP participated in the India-Peru FTA negotiations on 10th April 2024 wherein draft Pharma annex between India and Peru was discussed and summarized.

(iv) DoP participated in the technical meeting between Department of Health and Family Welfare and the Drug Administration of Vietnam on 12.04.2024 where in Circular No.15 on drug procurement policy of Vietnam, request for recognition of Indian pharmacopeia, verification of Indian CoPPs issues were discussed.

(v) Economic Advisor, DoP participated in the India-New Zealand Joint Trade Committee (JTC) on 26th - 27th April, 2024 at New Zealand under chairmanship of Commerce Secretary wherein market access issues of pharmaceuticals, creation of Joint Working Group on pharmaceuticals between New Zealand and India, possible collaboration with NIPERs, investment opportunities in pharma and medical devices sector and recognition and acceptance of Indian Pharmacopoeia (IP) were discussed.

2. Important policy matters held up on account of prolonged inter-ministerial consultations:

NIL

3. No. of cases of 'sanction for prosecution' pending for more than three months:

NIL

4. Particulars of cases in which there has been a departure from the Transaction of Business Rules or established policy of the Government:

NIL

5. Status of ongoing Swachhata Abhiyan (progress under Special Campaign):

Department is updating data relating to Secretariat Reforms and Swachhata Campaign in the SCDPM Portal of DARPG on monthly basis.

6. Status of Rationalization of Autonomous Bodies:

Completed

7. Information on the specific steps taken by the Ministry/Department for utilization of the Space Technology based tools and applications in Governance and Development:

NIL

8. Vacancy position of senior level appointments in the Ministry/Department, including Autonomous Bodies/PSUs:

(i) Department of Pharmaceuticals:

S. No.	Name of the posts	Sanctioned Strength	In-position	Vacancy	Group
1	Director/DS	07	06	01	A
2	Principal Private Secretary	02	00	02	A
3	Section Officer	16	13	03	B
	Total	25	19	06	

(ii) Public Sector Undertakings:

(a) Karnataka Antibiotics & Pharmaceuticals Limited (KAPL):

S. No.	Designation	Vacant Positions
1	Senior Manager	06
2	General Manager	06
	Total	12

(b) Hindustan Antibiotics Limited (HAL) (under strategic sale):

S.No.	Designation	Vacant Positions
1	CGM	03
2	GM	03
3	DGM	12
4	Manager	20
	Total	38

(c) Bengal Chemicals & Pharmaceuticals Limited (BCPL) (under strategic sale):

S.No.	Designation	Vacant Positions
1	Manager (Legal)	01
2	DGM (Marketing)	01
3	Sr. Manager (Purchase)	01
4	DGM (Finance)	01
5	Factory Head (DGM/AGM)	02
6	AGM (QA/QC)	01
	Total	07

(d) Indian Drugs & Pharmaceuticals Limited (IDPL) : NIL

(e) Rajasthan Drugs & Pharmaceuticals Limited (RDPL) : NIL

(iii) National Institute of Pharmaceutical Education and Research (NIPER): The applications for filling the vacant posts of Directors at NIPER Hyderabad and Hajipur were invited. After a thorough evaluation by the Search and Selection Committee, the applicants were shortlisted. Shortlisted applicants were interviewed on April 9, 2024, at ICMR, V. Ramalingaswami Bhawan, New Delhi.

9. List of cases in which ACC directions have not been complied with:

NIL

10. Details of FDI proposals cleared during the month and status of FDI proposals awaiting approval in the Ministry/Department:

(i)	Pending at beginning of the month	11
(ii)	Received during the month	1
(iii)	Disposed of during the month	2
(iv)	Pending at end of the month	10
(v)	FDI inflow approved during this month	NIL
